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Background: Epstain-Barr virus (EBV) can transform human B lymphocytes making them immortalized and
inducing tumorigenic ability in vitro, but the molecular mechanisms remain unclear. The aim of the present study is
to detect and analyze differentially expressed genes in two types of host cells, normal human lymphocytes and
coupled EBV-transformed lymphoblasts in vitro using gene chips, and to screen the key regulatory genes of
lymphocyte transformation induced by EB virus.
Methods: Fresh peripheral blood samples from seven healthy donors were collected. EBV was used to transform
lymphocytes in vitro. Total RNA was extracted from 7 cases of the normal lymphocytes and transformed
lymphoblasts respectively, marked with dihydroxyfluorane after reverse transcription, then hybridized with 4 × 44 K
Agilent human whole genome microarray. LIMMA, String, Cytoscape and other softwares were used to screen and
analyze differentially expressed genes. Real-time PCR was applied to verify the result of gene expression microarrays.
Results: There were 1745 differentially expressed genes that had been screened, including 917 up-regulated genes
and 828 down-regulated genes. According to the results of Generank, String and Cytoscape analyses, 38 genes may
be key controlled genes related to EBV-transformed lymphocytes, including 22 up-regulated genes(PLK1, E2F1,
AURKB, CDK2, PLCG2, CD80, PIK3R3, CDC20, CDC6, AURKA, CENPA, BUB1B, NUP37, MAD2L1, BIRC5, CDC25A, CCNB1,
RPA3, HJURP, KIF2C, CDK1, CDCA8) and 16 down-regulated genes(FYN, CD3D, CD4, CD3G, ZAP70, FOS, HCK, CD247,
PRKCQ, ITK, LCP2, CXCL1, CD8A, ITGB5, VAV3, CXCR4), which primarily control biological processes such as cell cycle,
mitosis, cytokine-cytokine pathway, immunity response and so on.
Conclusions: Human lymphocyte transformation induced by EB virus is a complicated process, involving
multiple-genes and –pathways in virus-host interactions. Global gene expression profile analysis showed that EBV
may transform human B lymphocytes by promoting cell cycle and mitosis, inhibiting cell apoptosis, hindering host
immune function and secretion of cytokines.
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Epstain-Barr virus (EBV) is closely associated with many
kinds of human tumors, including nasopharyngeal car-
cinoma, Burkitt lymphoma, Hodgkin's lymphoma, post-
transplant lymphoproliferative disorders (PTLD) and
others [1-3]. EBV can localize to B cells during latent
infections, since cells in this phase only express EBV la-
tent proteins with weak immunogenicity, thereby inhi-
biting the body’s ability to recognize and eliminate EBV-
infected cells. Under certain conditions and the actions
of some inducing factors, the latent infecting EBV is
reactivated, which can induce abnormal proliferation or
transformation of B cells, and might induce the genesis
of EBV associated tumors in some cases [1].
EBV can transform human B lymphocytes making
them immortalized and inducing tumorigenic ability
in vitro [4], but the molecular mechanisms remain un-
clear. In this study, normal peripheral blood lymphocytes
(PBLs) and coupled EBV transformed lymphoblastoid
cell lines (LCLs) were used as experimental models to
screen and compare the differentially expressed genes of
the two types of host cells in vitro, using human whole
genome microarrays, which possess different characteris-
tics and the same genetic background, and to analyze
the biological functions and interactions. Molecular
regulatory networks for EBV-induced human lympho-
cyte transformation were constructed to reveal the key
genes involved in the malignant transformation of EBV-
infected lymphocytes.
Materials and methods
Preparation of EBV suspension
B95-8 cells with well-defined morphologies were selected,
and the cell concentration was adjusted to 106-7/ml after
the last change of culture medium. Cells were then incu-
bated at 37°C and 5% CO2 incubator for 7 ~ 10 d. The
cultured solution was collected on the 10th day, and cen-
trifuged at 4000 r/min and 4°C for 30 min. The super-
natant was filtered through 0.45 μm microporous
membranes, subpackaged and sealed in freezing tubes
and stored at −80°C.
Establishment of LCLs
Fresh peripheral blood samples from seven healthy adult
donors were collected. Detection of EBV-VCA-IgG kit
(ELISA) for the serum and PCR amplification of EBV-
LMP1 in the whole blood DNA were used to verify EBV
infection status of the seven blood donors. All of the
seven donors were EBV-positive.
Normal PBLs were separated from fresh peripheral
blood samples using human lymphocyte separation
medium (Cat #LTS1077, Tian Jin Hao Yang Biological
Manufacture Co., Ltd.) and washed twice with RPMI
1640. A portion of the obtained PBLs were lysed withTrizol (Invitrogen, USA) and preserved at −80°C,
whereas the remaining PBLs were used for EBV trans-
formation according to the method described by David
[5]. Briefly, 2 ~ 3 × 106 normal PBLs were resuspended in
RPMI 1640 which contained 2 ml cyclosporine A ([San-
doz], with a final concentration of 2 μg/ml) and 25%
fetal bovine serum, and then inoculated to two wells of a
24-well plate. One ml of EBV suspension was added to
each well. A week later, lymphoblastoid-like changes in
cell morphology, volume enlarging, and cell aggregation
were observed. One-half of the cultivating mediums
were exchanged every 3 ~ 4 d. After four weeks, the cells
were transferred to a 25 ml culture bottle for subcultur-
ing. Resuscitation activity of seven samples of trans-
formed cells that were stored in liquid nitrogen for four
weeks was well, and could be used for continuous sub-
culturing. The successfully transformed LCLs were lysed
with Trizol and stored at −80°C.
Screening and analysis of differentially expressed genes
Total RNA was extracted from seven cases of the nor-
mal lymphocytes and transformed lymphoblasts, re-
spectively, marked with dihydroxyfluorane after reverse
transcription, then hybridized with Agilent whole gen-
ome microarray (Design ID. 14850). Agilent whole gen-
ome microarray and hybridization experiment were
provided and completed by Kangchen Bio-tech Inc
(Shanghai, China). Agilent whole genome microarray
included 41000 genes. Sixty-mer oligonucleotide probes
were manufactured using a computer-driven inkjet
printing process with Sureprint technology. Probe
designed was based on database resources including
Genbank, Ensemble and others, and was screened and
optimized following well-tested protocols. The microar-
rays were scanned using Agilent Microarray Scanner
(G2505B), with Agilent Feature Extraction and Agilent
Genepix GX software. LIMMA was used to screen dif-
ferentially expressed genes. Cluster 3.0 and Tree View
software were used for cluster analyses. GO and Pathway
software were used for analysis of gene function. Gener-
ank was used for gene ranking, and String and Cytos-
cape software were used to draw genetic interaction
network.
Real-time PCR verification
Four genes of interest were randomly selected from differ-
entially expressed genes screened in the above experi-
ments. Real-time PCR was performed with GADPH as an
internal control to verify the microarray results. Primer
sequences (5'-3') were as follows: E2F1: upstream GAAC
TGGGCTGCCGAGGT, downstream AGGACGTTGGT
GATGTCATAGAT; PLK1: upstream CAAGTGGGTGG
ACTATTCGGA, downstream CATTGTAGAGGATGAG
GCGTGT; BIRC5: upstream GAGTCCCTGGCTCCTCT
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FYN: upstream GGAAGGAGATTGGTGGGAA, down-
stream CACGGATAGAAAGTGAATAGGC; GADPH:
upstream GGGAAACTGTGGCGTGAT, downstream GA
GTGGGTGTCGCTGTTGA. Both normal lymphocytes
and transformed lymphoblasts were verified for seven
samples, and each experiment was repeated three times.
Results
EBV-transformed lymphoblastes
Morphological observation of successfully transformed
LCLs by inverted microscopy showed that cells were
rounded with obviously enlarged volumes, in which
some cells showed filiform antenna or pseudopods, clus-
tered and suspended growth. Occasionally tens or hun-
dreds of cells aggregated into cluster [5], and could be
subcultured in vitro infinitely (Figure l). RT-PCR results
of EBV-LMP1 of each cases of the LCLs derived from
the seven donors was positive.
Screening of differentially expressed genes
Microarray hybridization signal scanning showed that
fluorescence signaling was strong and uniform, quality
control was good, signal to noise ratio was low and the
signal intensity reflected the RNA expression of the sam-
ples. All the raw data was standardized by robust quan-
tile, then LIMMA software with false positive rate lessFigure 1 EBV-transformed lymphoblasts in vitro (×200). The volumes o
rounded or ellipsed, where some had filiform antenna or pseudopodia. Cethan 0.0001 and two-fold changes in differential expres-
sion as a standard was used in screening genes. Results
showed that there were 1,745 significantly differentially
expressed genes in each of the seven samples, including
917 up-regulated genes and 828 down-regulated genes.Biological function analysis of differentially expressed
genes
Hierarchical cluster analysis of differentially expressed
genes showed that the genes ultimately clustered into
two major branches, which indicated that the differen-
tially expressed genes were well distinguished between
normal PBLs and LCLs, and there existed significant dif-
ference between the expression patterns of two kinds of
host cell genes (Figure 2A).
Drawing and analysis of differentially expressed genes
interaction networks. Differentially expressed genes were
weight-sequenced according to the Generank algorithm
(Table 1). Generank was based on the premise that
nodes with more multiple of differentially expression
and joint-edges have more important biological function
[6,7]. Therefore, genes with the more advanced rankings
were more biologically important in the process of EBV-
transformation of lymphocytes. The 1,745 differentially
expressed genes were mapped to the "experiment" and
"database" sublibraries using String online software, and
the Confidence Score was set at a high confidence levelf successfully transformed lymphoblasts were significantly enlarged,
lls aggregated into clusters and could be subcultured in vitro infinitely.
Figure 2 Heatmap of differentially expressed genes. (A) Heatmap of 1745 differentially expressed genes. Norms 1 ~ 7: normal lymphocytes
1 ~ 7, Trans 1 ~ 7: EBV-transformed lymphoblasts 1 ~ 7. Dendrograms showed that the differentially expressed genes ultimately clustered into two
major branches, which indicated that the differentially expressed genes could distinguish normal PBLs and LCLs, and there existed significant
difference between the expression patterns of two kinds of host cell genes. (B) Heatmap of 38 key controled genes. the 38 genes also clustered
into two major branches, including 22 up-regulated genes and 16 down-regulated genes, and the expression of each genes can be notified.
Up-regulated genes were labeled in red, down-regulated genes were labeled in green, genes showed no significant expression difference were
labeled in black both in A and B.
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among 350 nodes with a total of 1,292 joint-edges, and
there were 88 nodes with ≥ 10 joint-edges, including
1051 joint-edges, accounting for 81% of the total, which
suggested that the 88 genes may have important func-
tions in EBV-transformed B lymphocytes (Figure 3).
Among these 88 nodes, 38 were either ranked in the top
100 up-regulated genes or the top 100 down-regulated
genes in Generank rank, which included 22 up-regulated
genes and 16 down-regulated genes (Figure 2B). Annota-
tion and analysis results of Genecards and Pathway
showed that the up-regulated genes were mainly related
to cell cycle, mitosis, DNA replication, and apoptosis
regulation, whereas the down-regulated genes were
mainly related to immunocyte activation, MHC-II/TCR/
BCR expression and interaction, and cytokine inter-
action (Table 1).
Results of real-time PCR verification
Real-time PCR results showed that trends in expression
change for the randomly selected four genes wereconsistent with the microarray results. PLK1, E2F1,
BIRC5 showed a high expression level in LCLs, and low
expression in FYN (Table 2), verifying that the micro-
array results were accurate and reliable.
Discussion
The accumulation of high-throughput gene and protein
expression profile data has greatly promoted the applica-
tion of computer science and technology in functional
gene studies. However, complex biological functions are
not simply controlled by a single gene, as certain bio-
logical processes are realized by the cooperation of a
series of genes. In this study, normal peripheral blood
lymphocytes (PBLs) and coupled EBV-transformed lym-
phoblastoid cell lines (LCLs) were analyzed using Agi-
lent human whole genome microarrays, in which 1,745
differentially expressed genes were screened. Our results
indicated that EBV-induced human lymphocyte trans-
formation was a process involving multiple genes and
pathways in virus-host interactions. Hierarchical cluster-
ing analysis of the 1,745 differentially expressed genes
Table 1 Functional annotation of 38 differentially expressed genes
Notes Generank Fold Change Edges Gene Annotation
Up-regulated genes
PLK1 12.04 5.44 49 regulates M phase of cell cycle
E2F1 10.51 3.01 18 mediate cell proliferation and p53-dependent/indepent apoptosis
AURKB 10.07 5.13 39 mitosis checkpoint
CDK2 9.34 2.30 29 cell cycle checkpoint
PLCG2 8.93 2.18 10 crucial enzyme in transmembrane signaling
CD80 8.48 5.09 10 costimulatory signal for T cell activation
PIK3R3 7.39 2.94 15 responsible for a range of cell functions
CDC20 7.30 5.14 36 regulates multiple points of cell cycle
CDC6 6.90 5.75 26 initiates of DNA repliaction
AURKA 6.88 5.27 21 mitosis checkpoint
CENPA 6.87 6.87 28 mitosis checkpoint
BUB1B 6.81 6.55 34 mitosis checkpoint
NUP37 6.37 3.08 29 mitosis checkpoint
MAD2L1 6.32 4.08 16 spindle-assembly checkpoint
BIRC5 6.04 5.53 36 negative regulator of apoptosis
CDC25A 6.00 4.77 16 cell cycle checkpoint
CCNB1 5.81 5.81 18 cell cycle checkpoint
RPA3 5.64 2.42 17 required for DNA recombination, repair and replication
HJURP 5.62 5.62 13 fuctions in chromosome segregation
KIF2C 5.59 4.70 27 fuctions in chromosome segregation
CDK1 5.50 5.50 38 cell cycle checkpoint
CDCA8 5.45 5.27 26 mitosis checkpoint
Down-regulated genes
FYN −19.27 −4.92 34 involved in B/T cell activation
CD3D −12.04 −10.50 19 involved in T/B-cell activation
CD4 −11.92 −4.97 20 MHC-II/T-cell receptor interacton
CD3G −11.91 −9.81 19 involved in T-cell activation
ZAP70 −11.69 −6.20 21 involved in T-cell development and activation
FOS −11.29 −8.32 14 involved in AP-1 and BCR/TCR signal pathway
HCK −10.11 −5.28 17 contributes to neutrophil migration and degranulation
CD247 −9.16 −9.16 19 regulates TCR expression and signal transduction
PRKCQ −9.10 −7.15 10 involved in T-cell activation
ITK −8.93 −9.22 15 involved in T-cell proliferation and differentiation
LCP2 −8.53 −4.27 14 involved in T-cell antigen receptor mediated signaling
CXCL1 −8.19 −8.19 13 has chemotactic activity for neutrophils
CD8A −8.08 −9.86 15 involved in T-cell mediated killing
ITGB5 −7.72 −5.16 11 receptor for fibronectin
VAV3 −7.60 −4.55 10 plays an important role in angiogenesis and FcERI signaling pathway
CXCR4 −7.20 −4.22 10 cytokine-cytokine receptor interaction
Note: Annotation and analysis results showed that the up-regulated genes were mainly related to cell cycle, mitosis, DNA replication, apoptosis regulation
and etc., and the down-regulated genes were mainly related to T-cell (immunocytes) activation, MHC-II/TCR/BCR expression and interaction, cytokines interaction
and etc.
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mal PBLs and LCLs, as there were significant differences
between the expression patterns of the two types of host
cells. There were 88 differentially expressed genes with ≥
10 joint-edges, accounted for 81% of the total jonit-
edges, which suggested that these genes may play an im-
portant role in the process of EBV transformation of B
lymphocytes.
Cell cycle and mitosis promoted differentially expressed
genes
Viral genes can induce changes in the cell cycle of the
host cell during the immortalization of B lymphocytes
by EBV [8]. EBV latent proteins can up-regulate cyclinFigure 3 Interaction networks maps of differentially expressed genes
labeled in green. △ labeled genes had≥ 10 joint-edges, labeled nodes wer
top 100 of down-regulated genes in the Generank rank. There were 88 nod
which accounted for 81% of the total.D1 expression in host cell, initiate the cell cycle and pro-
mote the G1-S phase transition through several signaling
pathways [9,10]. EBV can also induce the up-regulation
of CDK2 and CDK1 in the host cell [11]. CDK2 not only
acted on the boundary of G1/S phase, but also had a key
regulatory effect on S phase progression and DNA syn-
thesis. CDK1 could promote the end of S phase and start
G2 phase. The cyclin B1/CDK1 complex triggered G2/M
phase transition and promoted mitosis to enter into ana-
phase. The activation of CDK2 was dependent on the
regulation of transcription factor E2F. Research has
shown that EBNA-6 and EBV transcription activation
factor Zta and Rta could induce up-regulation of E2F1
in the host cell [12,13]. Annotation of differentially. Up-regulated genes were labeled in red, down-regulated genes were
e the 38 genes that ranked the top 100 of up-regulated genes or the
es with≥ 10 joint-edges in the map, including 1051 joint-edges,
Table 2 Results of real-time PCR verification
Gene Cell Number Calc Conc P-value
E2F1 Norms 7 7.97 ± 0.15 1.55E-11
Trans 7 88.49 ± 1.75
PLK1 Norms 7 2.12 ± 0.16 6.65E-19
Trans 7 15.97 ± 0.33
BIRC5 Norms 7 2.01 ± 0.10 7.88E-10
Trans 7 14.54 ± 0.58
FYN Norms 7 162.16± 2.92 2.83E-12
Trans 7 6.35 ± 0.48
Note: Norms--normal lymphocytes; Trans--transformed lymphoblasts. Calc
Conc--calculation concentration.
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that up-regulated genes (CDC6, RPA3, etc.) participated
in the initiation of DNA replication and DNA recombin-
ation. Therefore, we presumed that EBV might promote
the progression of the cell cycle, induce B lymphocyte
transformation and obtain infinite proliferation ability
through up-regulating of certain cell cycle related genes.
Lacoste et al (2010) found that chromosome re-
arrangement might occur in subcultured early phase
EBV-LCLs, mainly including chromosome deletion,
chromosome fragments, dicentric chromosomes and
unbalanced chromosome translocation, and aneuploidy
variation may occur during the 12th week post-infection
[14], suggesting that EBV can induce unstable variation
of the host cell genome. Gruhne et al (2009) confirmed
that EBNA-1 induced DNA damage, LMP-1 inhibited
DNA repair and apoptosis regulation, and EBNA-3 C
down-regulated BubR1 transcription resulting host cell
released CDC20 and then passived spindle checkpiont
[15]. Pan et al (2009) showed that the cell spindle
checkpoint could be disturbed by EBNA2 through
down-regulation of MAD2 and up-regulation of PLK1,
resulting in unstable chromosome variation [16]. Up-
regulation of several spindle checkpoint related genes
were observed in this study, including PLK1, AURKA,
AURKB, NUP37, CENPA, BUB1B, CDCA8 and others.
Considering that cell aneuploidy variation was mostly
induced by disruption in the spindle checkpoint [17], we
presumed that EBV might up-regulate the expression of
a series of spindle checkpoint related genes, thus indu-
cing change in the stability of the genome, as well as in-
ducing B lymphocyte cell transformation and abnormal
proliferation.
Cell apoptosis inhibited differentially expressed genes
Abnormal cell proliferation has a close relation with dis-
ordered apoptosis regulation. Ng Siok-Bian et al [18]
reported that LMP1 could activate NF-κB and MYC to
mediate the high expression of the BIRC5 (Survivin), an
inhibitor of apoptosis protein, in extranodal nasal-typeNK/T cell lymphoma cells. However, LU et al [19]
proposed that EBNA1 formed a complex with Sp1 or
Sp1-like protein, and the cis-element of the complex
combined with the BIRC5 promoter induced the up-
regulation of BIRC5. In addition, Ando et al [20]
reported that there existed a sequence-specific PLK1
binding region in P53, where PLK1 inhibited the tran-
scription activity and apoptosis regulation ability of p53
by binding to this region. The high expression of BIRC5
and PLK1 in LCLs in this study suggested that EBV can
inhibit B cell apoptosis and impel cell immortalization
through multiple ways.
Host immune function hindered differentially expressed
genes
Among the EBV-induced down-regulated genes, several
were involved in T/B cell activation of the host, suggest-
ing that EBV regulated changes in immune function of
the host during transformation of B cells. A microarray
experiment conducted by Sengupta et al [21] confirmed
that EBV could limit the expression of MHC-I chain-
related genes in nasopharyngeal carcinoma cells. Rovedo
et al [22] showed that LMP2A can bind to the SH-2
functional domain of FYN and block normal BCR signal
transduction. The binding of FYN specific sequences
and CD3 is required for T cell activation [23]. Gene
function annotation showed that down-regulated genes,
such as CD3D, CD4, CD3G, ZAP70, LCP2, ITK, etc.,
were involved in immunocytes activation and immune-
related signal pathways, suggesting that EBV may inhibit
the expression of these genes to hinder the normal im-
mune surveillance and clearance of the host, which may
allow virus-infected cells to evade immune surveillance,
and ultimately induce the transformation or even malig-
nancy of EBV-infected cells. Our previous experiments
have confirmed that human-derived B-cell lymphoma
could be induced in SCID mice transplanted with EBV
seropositive donor’s lymphocytes [24,25], which sup-
ported the hypothesis that EBV-induced lymphomas
were related to immune suppression or deficiency.
EBV BZLF1 is the switch for EBV latent state into lytic
state. The expression of the BZLF1 gene is initiated from
the promoter Zp, which is normally suppressed in EBV-
transformed B cell. Liang et al [26] demonstrated BZLF1
gene can be activated by TGF-β through the cooperation
of Smad3/Smad4 and c-Jun/c-Fos that formed a com-
plex. The proto-oncogene product c-Fos is a component
of the transcription factor AP-1. Mao et al [27] demon-
strated fos protein was rarely expressed in the primary
cutaneous B-cell lymphoma (PCBCL), and the result of
KEGG pathway analysis showed that fos participate in
B/T cell receptor signalling pathway. In this study, we
hypothesized EBV may down-regulated fos to maintain
its latent infection and to evade host immune
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B lymphocytes.
It is noteworthy that other studies had showed that
EBV could change cytokine secretion of the host cell,
thereby inhibiting normal immune function, and was
also an important regulatory factor for the transform-
ation or malignant change of the B lymphocytes induced
by EBV. Ehlin-Henriksson et al [28] indicated that
EBNA2 and LMP1 can down-regulate the expression of
CXCR4 in B-cell lymphoma cells. Chen et al [29] con-
firmed that EBNA-3B inhibited the expression of
CXCR4 in EBV-infected B cells, thus affecting the B-cell
homing and disturbing the normal immune barrier of
the host. Down-regulation of cytokine-related genes-
CXCR4 and CXCL1 in LCLs were also observed in this
study. Therefore, we presumed that the change in ex-
pression of cytokine-related genes induced by EBV was
also a regulatory factor in hindering host immune func-
tion and transformation of B lymphocytes.
In summary, EBV-induced B lymphocyte transform-
ation was a complicated process, which involved many
genes and pathways changes between virus and host
interaction. Global gene expression profile analysis
showed that there existed significant differences in the
gene expression patterns between LCLs and normal host
lymphocytes, and EBV may induce the transformation of
human B lymphocytes by promoting cell cycle and mi-
tosis, inhibiting cell apoptosis, regulating cytokine secre-
tion, and hindering normal immune function. Our
present results filtered out 38 key regulatory genes. The
function and specific effect in EBV-transformed lympho-
cytes of the these key regulatory genes screened from
EBV-transformed lymphoblastoid cell lines (LCLs) need
to be further studied. This study provided important in-
formation on the molecular mechanism of lymphocyte
transformation by EBV, and laid a foundation for subse-
quent gene validation and functional studies.
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